Frequently Asked Questions
The market is segmented based on , By Treatment (Hormone Therapies, Xofigo, Sipuleucel-T, Cabazitaxel, Docetaxel, and Others), Route of Administration (Oral, Parenteral, and Others), Form (Solid Dosage Form, Liquid Dosage Form), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031.
.
The Global Metastatic Castrate Resistant Prostate Cancer Treatment Market size was valued at USD 11.10 USD Billion in 2023.
The Global Metastatic Castrate Resistant Prostate Cancer Treatment Market is projected to grow at a CAGR of 8.1% during the forecast period of 2024 to 2031.
The major players operating in the market include F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co. Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Bausch Health Companies Inc. (Canada), Takeda Pharmaceutical Company Limited (Japan), AbbVie Inc. (U.S.), Merck KGaA (Germany).
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.
